A real-life study of the positive response to DAA-based therapies for hepatitis C in Brazil

This study is the first of this magnitude to be held in a Latin-American country with high SVR results, supported by a free-of-charge universal and public health system. The high performance found in this study gives support to the Brazilian public health policy decision of adopting DAA-based therapies as a strategy to eliminate HCV by 2030.PMID:33836175 | DOI:10.1016/j.bjid.2021.101573

Source: Braz J Infect Dis - April 9, 2021 Category: Infectious Diseases Authors: Simone Monzani Vivaldini Rachel Abra ão Ribeiro Gl áucio Mosimann Júnior Karen Cristine Tonini Gerson Fernando Mendes Pereira Wildo Navegantes de Ara újo Source Type: research